Biosynex SA (ENXTPA:ALBIO) bid to acquire remaining 74.93% stakes in Theradiag SA (ENXTPA:ALTER) on September 23, 2022. Biosynex SA will acquire the remaining shares at €2.30 per share. The Board of Directors of Theradiag unanimously approved the transaction. The transaction is subject to regulatory approval. Biosynex does not intend to request the implementation of a squeeze-out procedure at the end of this offer. The offer took place from January 18, 2023 to January 31 January 2023. Fieldfisher is acting as legal counsel and Maxime Hazim of Crowe HAF is acting as financial advisor to Theradiag in this transaction. Marc Petitier, Alexandre Jaurett and Alexandre Ippolito of White & Case LLP (Paris) is acting as legal counsel to Biosynex.

Biosynex SA (ENXTPA:ALBIO) completed the acquisition of additional 46.52% stake in Theradiag SA (ENXTPA:ALTER) for €21.6 million on January 31, 2023. Following this transaction, Biosynex holds 9,382,354 shares representing 71.52% stake in Theradiag.